Login to Your Account

Takeover Target?

Elan to Spin Out Drug Discovery into Neotope

By Cormac Sheridan
Staff Writer

Wednesday, August 15, 2012
DUBLIN, Ireland – Elan Corp. plc is hiving off its early stage neurology drug discovery activity into a new entity, Neotope Biosciences, which will begin life with $120 million to $130 million in cash and seek a listing on an as yet to be determined U.S. exchange.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription